ReviewBreast care (Basel, Switzerland)2017

Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients.

Lidia Kowalczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.